The Obesity Action Coalition (OAC) is pleased to share that Altimmune, Inc. has joined the OAC’s Chairman’s Council at the Patron level. Thank you, Altimmune, Inc., for supporting and championing the OAC’s mission.

About Altimmune, Inc.

Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product, pemvidutide, is a GLP-1/glucagon agonist that is being developed for the treatment of obesity and NASH.

To learn more, visit

About the OAC Chairman’s Council

The OAC is honored that Altimmune, Inc. has chosen to support our organization at the Patron level through the Chairman’s Council as we strive to partner with industry leaders who share our mission of supporting and empowering individuals in their health journeys.

The OAC welcomes individuals, organizations, or companies who wish to join our highest level of OAC Membership and receive maximum benefits. Our Chairman’s Council is an excellent way to give back to the cause and play an integral role in making the world a better place for people with obesity. To learn more about the OAC’s Chairman’s Council, click here.